NOVO NORDISK A/S (NYSE: NVO)

NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: 28 minutes ago

36.04

-0.36 (-0.99%)

Add to watchlist

Previous Close	36.40
Open	36.31
Volume	14,614,205
Avg. Volume (3M)	24,216,549
Market Cap	161,212,956,672

Price / Earnings (TTM)	10.12
Price / Earnings (Forward)	10.87
Price / Sales	3.43
Price / Book	5.45

52 Weeks Range	35.85 (-0%) — 81.44 (125%)
Earnings Date	6 May 2026
TTM Dividend Yield	3.05%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Mixed
	Drug Manufacturers - General (Global)	Bullish	Mixed
Stock	Novo Nordisk A/S	Bullish	Bearish

AIStockmoo Score

1.6

Analyst Consensus	3.0
Insider Activity	NA
Price Volatility	3.5
Technical Moving Averages	2.5
Technical Oscillators	-2.5
Average	1.63

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
NVO	161 B	3.05%	10.12	5.45
NVS	290 B	2.46%	20.95	6.04
LLY	786 B	0.63%	38.25	30.51
JNJ	579 B	2.21%	21.80	6.95
ABBV	370 B	0.78%	88.35	50.46
MRK	296 B	0.68%	16.41	5.37

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Core
% Held by Insiders	0.01%
% Held by Institutions	9.85%

Ownership

Name	Date	Shares Held
Loomis Sayles & Co L P	31 Dec 2025	17,135,384
Franklin Resources Inc	31 Dec 2025	14,702,508
Folketrygdfondet	31 Dec 2025	10,164,137
Fisher Asset Management, Llc	31 Dec 2025	9,784,222
Everett Harris & Co /Ca/	31 Dec 2025	6,407,366
State Farm Mutual Automobile Insurance Co	31 Dec 2025	6,142,778

52 Weeks Range	35.85 (-0%) — 81.44 (125%)
Price Target Range	41.00 (13%) — 73.50 (103%)
High	73.50 (CICC, 103.94%)	Buy
Median	57.25 (58.85%)
Low	41.00 (Goldman Sachs, 13.76%)	Hold
Average	57.25 (58.85%)
Total	1 Buy, 1 Hold
Avg. Price @ Call	48.29

Firm	Date	Target Price	Call	Price @ Call
Goldman Sachs	02 Mar 2026	41.00 (13.76%)	Hold	37.76
CICC	09 Jan 2026	73.50 (103.94%)	Buy	58.81

Date	Type	Details
23 Mar 2026	CNBC	GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
19 Mar 2026	CNBC	FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
05 Mar 2026	CNBC	Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
24 Feb 2026	CNBC	Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
11 Feb 2026	CNBC	Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
11 Feb 2026	CNBC	Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
09 Feb 2026	CNBC	Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
09 Feb 2026	CNBC	FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
09 Feb 2026	CNBC	Super Bowl 60 recap: Rewatch all the top commercials from advertising's biggest night
06 Feb 2026	CNBC	White House launches direct-to-consumer drug site TrumpRx. Here's what to know
05 Feb 2026	Announcement	Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
05 Feb 2026	Announcement	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
05 Feb 2026	Announcement	Lexaria Announces Positive Final Results From Human Pilot Study #5
04 Feb 2026	CNBC	Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
04 Feb 2026	Announcement	Novo Nordisk files annual report with the SEC
04 Feb 2026	CNBC	Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
04 Feb 2026	Announcement	Novo Nordisk has published its annual report for 2025
04 Feb 2026	Announcement	Novo Nordisk initiates 2026 share repurchase programme
03 Feb 2026	Announcement	Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
03 Feb 2026	Announcement	Novo Nordisk releases 2026 sales and operating profit outlook
03 Feb 2026	CNBC	Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
02 Feb 2026	Announcement	Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
31 Jan 2026	Announcement	New employee representative on the Board of Directors of Novo Nordisk A/S
30 Jan 2026	CNBC	Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
30 Jan 2026	CNBC	Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
23 Jan 2026	CNBC	What obesity drugmakers see next in the market: More pills, easier access and drug combinations
20 Jan 2026	Announcement	Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
20 Jan 2026	CNBC	Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
16 Jan 2026	CNBC	Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026	CNBC	2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026	CNBC	Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
05 Jan 2026	CNBC	First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
05 Jan 2026	Announcement	Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
31 Dec 2025	Announcement	Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
Show more

TTM Dividend Yield	3.05%
5Y Average Dividend Yield	2.17%
Payout Ratio	47.09%

Ex Date	Announcement Date	Payment Date	Details
31 Mar 2025	05 Feb 2025	08 Apr 2025	1.099206 Cash
16 Aug 2024	06 Aug 2024	26 Aug 2024	0.5126402 Cash
22 Mar 2024	31 Jan 2024	02 Apr 2024	0.92985 Cash
18 Aug 2023	10 Aug 2023	29 Aug 2023	0.8835613 Cash
24 Mar 2023	02 Feb 2023	04 Apr 2023	1.1887415 Cash
12 Aug 2022	04 Aug 2022	23 Aug 2022	0.5835507 Cash
25 Mar 2022	02 Mar 2022	05 Apr 2022	1.022423 Cash
16 Aug 2021	-	25 Aug 2021	0.5502889 Cash
26 Mar 2021	-	07 Apr 2021	0.922122 Cash
14 Aug 2020	06 Aug 2020	25 Aug 2020	0.5177774 Cash
27 Mar 2020	06 Feb 2020	07 Apr 2020	0.7826048 Cash
16 Aug 2019	10 Aug 2019	27 Aug 2019	0.449438 Cash
22 Mar 2019	05 Feb 2019	02 Apr 2019	0.777006 Cash
17 Aug 2018	09 Aug 2018	28 Aug 2018	0.462327 Cash
23 Mar 2018	24 Mar 2018	03 Apr 2018	0.805982 Cash
17 Aug 2017	-	29 Aug 2017	0.33589 Cash
23 Mar 2017	-	04 Apr 2017	0.479369 Cash
11 Aug 2016	-	23 Aug 2016	0.331026 Cash
18 Mar 2016	-	30 Mar 2016	0.69943 Cash
19 Mar 2015	-	31 Mar 2015	0.532885 Cash
21 Mar 2014	-	02 Apr 2014	0.606122 Cash
21 Mar 2013	-	02 Apr 2013	2.264307 Cash
22 Mar 2012	-	03 Apr 2012	1.831902 Cash
24 Mar 2011	-	05 Apr 2011	1.357901 Cash
25 Mar 2010	-	07 Apr 2010	0.978615 Cash
19 Mar 2009	-	31 Mar 2009	0.781532 Cash
13 Mar 2008	-	25 Mar 2008	0.678462 Cash
08 Mar 2007	-	20 Mar 2007	0.891779 Cash
09 Mar 2006	-	21 Mar 2006	0.691753 Cash
10 Mar 2005	-	22 Mar 2005	0.61725 Cash
17 Mar 2004	-	29 Mar 2004	0.52096 Cash
26 Mar 2003	-	07 Apr 2003	0.37647 Cash
13 Mar 2002	-	25 Mar 2002	0.2848 Cash
21 Mar 2001	-	02 Apr 2001	0.5681 Cash
24 Mar 2000	-	06 Apr 2000	0.4672 Cash
25 Mar 1999	-	06 Apr 1999	0.4182 Cash
27 Mar 1998	-	08 Apr 1998	0.3051 Cash
25 Apr 1997	-	07 May 1997	0.239 Cash
01 May 1996	-	14 May 1996	0.1806 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	1.10	1	2.16
2024	1.44	2	1.68
2023	2.07	2	2.00
2022	1.61	2	2.37
2021	1.47	2	2.63
2020	1.30	2	3.72
2019	1.23	2	4.24
2018	1.27	2	5.51
2017	0.815	2	3.04
2016	1.03	2	5.75
2015	0.533	1	1.84
2014	0.606	1	2.86
2013	2.26	1	12.26
2012	1.83	1	11.22
2011	1.36	1	11.78
2010	0.979	1	8.69
2009	0.782	1	12.24
2008	0.678	1	13.20
2007	0.892	1	13.75
2006	0.692	1	16.54
2005	0.617	1	21.94
2004	0.521	1	19.20
2003	0.376	1	18.38
2002	0.285	1	19.71
2001	0.568	1	28.33
2000	0.467	1	26.40
1999	0.418	1	32.36
1998	0.305	1	22.94
1997	0.239	1	16.57
1996	0.181	1	19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	34.51%
Operating Margin (TTM)	49.68%
Diluted EPS (TTM)	3.67
Quarterly Revenue Growth (YOY)	19.50%
Quarterly Earnings Growth (YOY)	14.30%

Total Debt/Equity (MRQ)	85.70%
Current Ratio (MRQ)	0.740
Operating Cash Flow (TTM)	131.24 B
Levered Free Cash Flow (TTM)	77.73 B

Return on Assets (TTM)	23.29%
Return on Equity (TTM)	88.12%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)